Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | PI4KA | P42356 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5806556 | 0.81 | MLYCD (0.34) | KMT2A | |
| SCHEMBL2994913 | 0.79 | — | — | |
| SCHEMBL3008881 | 0.79 | RIPK1 (0.33) | MAPTALDH1A1HPGDLMNATSHR | |
| SCHEMBL22372214 | 0.78 | TRPM8 (0.35) | KDM4E | |
| SCHEMBL3010551 | 0.76 | TP53 (0.44) | MAPTALDH1A1HPGDKDM4E | |
| SCHEMBL5160919 | 0.76 | — | — | |
| SCHEMBL22372020 | 0.76 | SCN9A (0.36) | MAPT | |
| SCHEMBL5752399 | 0.75 | — | — | |
| SCHEMBL5219663 | 0.73 | APOBEC3A (0.52) | ALDH1A1SMN1; SMN2HPGDKMT2ALMNA | |
| SCHEMBL31738006 | 0.73 | SLC6A4 (0.39) | HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264138-B2 | Process for the preparation of microbiocidal oxadiazole derivatives | SYNGENTA CROP PROTECTION AG (CH) | 2025-04-01 | — | — | US | disclosed |
| US-20220194907-A1 | PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2022-06-23 | — | — | US | disclosed |
| WO-2015035062-A1 | ANTIPROLIFERATIVE COMPOUNDS | GENENTECH, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| US-20130023525-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-24 | — | — | US | disclosed |
| US-8193352-B2 | 2-(3-Ethyl-ureido)-6-pyridin-3-yl-3H-benzoimidazole-4-carboxylic acid methyl ester; for treating bacterial infections in mammals; useful in treating or lessening severity of urinary tract infections, pneumonia, prostatitis, skin and soft tissue infections, intra-abdominal infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-05 | — | — | US | disclosed |
| US-8188095-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120010222-A1 | Gyrase Inhibitors and Uses Thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | US | disclosed |
| US-8067606-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-29 | — | — | US | disclosed |
| US-8034832-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-11 | — | — | US | disclosed |
| WO-2011079118-A1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC (US) | 2011-06-30 | — | — | WO | disclosed |
| EP-2167474-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | Valletta Health IP EE B.V. (NL) | 2010-03-31 | — | — | EP | disclosed |
| US-20100063069-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-11 | — | — | US | disclosed |
| US-20090325935-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-12-31 | — | — | US | disclosed |
| US-20090325955-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-12-31 | — | — | US | disclosed |
| US-7618974-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-17 | — | — | US | disclosed |
| US-20090176771-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-7495014-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| WO-2008153385-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | VALLETTA HEALTH B.V. (NL) | 2008-12-18 | — | — | WO | disclosed |
| CN-1865248-A | Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity | BAYER PHARMACEUTICALS CORP (US) | 2006-11-22 | — | — | CN | disclosed |
| CN-1599724-A | Imidazole-4-carboxamide derivatives, their preparation and use in the treatment of obesity | BAYER PHARMACEUTICALS CORPORAT (US) | 2005-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010222-A1 | Gyrase Inhibitors and Uses Thereof | TOP1, TOP2A, NQO2 | MALT1 3256/4885NQO2 3/4885MAPT 4342/4885 |
| US-20090176771-A1 | GYRASE INHIBITORS AND USES THEREOF | TOP1, TOP2A, TOP2B | MALT1 2721/4885NQO2 9/4885MAPT 3821/4885 |
| US-20090325955-A1 | GYRASE INHIBITORS AND USES THEREOF | TOP1, TOP2A, NQO2 | MALT1 3256/4885NQO2 3/4885MAPT 4342/4885 |
| US-12264138-B2 | Process for the preparation of microbiocidal oxadiazole derivatives | CYP51A1, MPO, NOX5 | MALT1 898/4885NQO2 486/4885MAPT 4752/4885 |
| US-20130023525-A1 | GYRASE INHIBITORS AND USES THEREOF | TOP1, TOP2A, TOP2B | MALT1 2721/4885NQO2 9/4885MAPT 3821/4885 |
| US-20090325935-A1 | GYRASE INHIBITORS AND USES THEREOF | TOP1, TOP2A, TOP2B | MALT1 2750/4885NQO2 9/4885MAPT 3810/4885 |
| US-20220194907-A1 | PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES | CYP51A1, MPO, NOX5 | MALT1 898/4885NQO2 486/4885MAPT 4752/4885 |
| US-20100063069-A1 | GYRASE INHIBITORS AND USES THEREOF | TOP1, TOP2A, TOP2B | MALT1 2750/4885NQO2 9/4885MAPT 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.